Table 2.
Disease or Condition |
Model | EC-EV phenotypes | Levels |
EV
medium |
Other major findings | Reference |
---|---|---|---|---|---|---|
PH | Patients |
CD62E+ CD144+ CD31+/CD41- |
↑ ↑ ↑ |
Plasma | • EC-MVs (CD31+/CD41- and CD144+) predict hemodynamic severity • CD45+ increased, no changes in CD41+ |
(Amabile et al. 2008) |
Patients |
CD62E+ CD144+ CD31+/CD41- |
↑ ↑ |
Plasma | • CD62E+ predict poor outcomes • CD45+ increased |
(Amabile et al. 2009) | |
Patients | CD105+ | ↑ | Plasma | • TF+ increased • TF+ correlate with severity of PH |
(Bakouboula et al. 2008) | |
Patients (CTEPH) |
CD105+ CD144+ |
↑ | Plasma | CD105+ from patients stimulate increased CD105 expression in vitro, promote angiogenesis, and inhibit apoptosis in ECs | (Belik et al. 2016) | |
Patients | CD62E+ | ↑ | Plasma | • CD31/CD61+ (PMVs) and CD11b+ increased • Patients with thrombo-embolic PH had increased CD62E+ compared to non-embolic PH |
(Diehl et al. 2011) | |
Patients (IPAH) |
CD31+/CD42b- | ↑ | Plasma | CD39 ectonucleotidase expression was increased on all EV populations | (Visovatti et al. 2012) | |
Monocrotaline PH rat model | CD31+/CD42b- | ↑ | Plasma | CD31+/CD42b- increased during disease but treatment with hepatocyte growth factor reduced EVs and reversed PAH | (Chen et al. 2014) | |
Hypoxic PH rat model | CD54+ | ─ |
Plasma | • CD61+ (PMVs) and erythrocyte MVs increased • No changes in CD45+ • Total EVs increased in hypoxia and total EVs impaired endothelial-dependent relaxation |
(Tual-Chalot et al. 2010) | |
Su5416/Hypoxia PAH rat model | Total EVs | ↑ | Plasma | EVs from PAH stimulate adhesion molecule expression | (Blair, Haven, and Bauer 2016) | |
Monocrotaline PH murine model | Total EVs | ↑ | Plasma | EVs from monocrotaline-PH mice injected into healthy mice induced PH; exosomes found to be the injury-inducing population | (Aliotta et al. 2016; Aliotta et al. 2013) | |
ARDS | Patients | EC-EVs not assessed | Pulmonary edema fluid | Procoagulant alveolar EVs are increased in ARDS | (Bastarache et al. 2009) | |
Patients | CD31+/CD41- | ↑ | BAL | • EC-EVs were detectable in 6/52 ARDS patients • Leukocyte EVs are increased in ARDS |
(Guervilly et al. 2011) | |
Patients | EC-EVs not assessed | Plasma | Phosphatidylserine+ EVs are decreased in ICU patients who develop ARDS | (Shaver et al. 2017) | ||
Patients & ALI murine model- LPS (IP) |
CD31+/CD41- | ↑ | Plasma | EC pyroptosis induces MV release in a caspase-dependent manner | (Cheng et al. 2017) | |
ALI murine model-LPS (IP) |
CD144+ CD62E+ CD31+ CD54+ |
↑ ↑ ↑ ↑ |
Plasma | Simvastatin protects against ALI and reduces plasma EC-MV levels | (Yu et al. 2017) | |
ALI rat model- LPS (IT) | CD54+ | ↑ | Plasma | Plasma MVs from LPS-treated rats induce pulmonary inflammation | (Li et al. 2015) | |
ALI murine model-LPS (IT) | EC-EVs not assessed | BAL | Alveolar macrophage and epithelial EVs are increased in ALI | (Soni et al. 2016) | ||
VILI murine model | CD62E+ | ↑ | Plasma, BAL | Pathologic mechanical stretch-induced EC-MVs cause lung injury | (Letsiou et al. 2015) | |
VILI murine model |
CD144+ CD62E+ CD31+/CD41- CD54+ |
↑ ↑ ↑ ↑ |
Plasma | Treatment of mice with a protective agent (Tetramethylpyrazine) reduces VILI and EC-MV levels | (Pan et al. 2017) | |
VILI rat model | CD31+ | ↑ | Plasma | Lung tissue PECAM −1 (CD31) levels are reduced in VILI | (Cabrera-Benitez et al. 2015) | |
COPD | Patients (smokers with signs of early emphysema) | CD31+/CD42b- | ↑ | Plasma | 76% of EC-MVs were angiotensin converting enzyme positive, indicating the pulmonary capillaries as their main source | (Gordon et al. 2011) |
Patients (stable COPD) |
CD144+ CD31+/CD41- CD62E+ CD146+ |
↑ ↑ ↑ ─ |
Plasma | • CD62E+ MVs are higher in patients with frequent exacerbations | (Takahashi et al. 2012) | |
Patients |
CD31+/CD42-
CD62E+ |
↑ ↑ |
Plasma | • CD31+/CD42- were increased in mild and severe COPD • CD62E+ were increased in severe COPD |
(Thomashow et al. 2013) | |
Patients | CD31+ | ↑ | Sputum | Positive correlation of MV levels and lung damage | (Lacedonia et al. 2016) | |
Patients (Smokers) |
CD31+/CD42b- | ↑ | Plasma | EC-MV levels are not altered in COPD smokers following smoking cessation | (Strulovici-Barel et al. 2016) | |
Patients (Secondhand smoke) |
CD144+ CD31+/CD41- CD62E+ |
↑ ↑ ↑ |
Plasma | Secondhand smoke results in dysfunctional endothelial progenitor cell mobilization | (Heiss et al. 2008) | |
Patients & cigarette smoke murine model | CD31+/CD42b- | ↑ | Plasma | EC-MV levels are higher in mild COPD compared to severe COPD | (Serban et al. 2016) | |
Cigarette smoke (Rat model) |
CD31+/CD42b- | ↑ | Plasma | Negative correlation between EC-MVs and dynamic compliance | (Liu et al. 2014) | |
OSA | Patients | CD31+/CD42b- | ↑ | Blood | EMVs negatively correlate with circulating EPCs | (Jelic et al. 2009) |
Patients (Minimally symptomatic OSA) | CD31+/CD41- | ─ | Plasma | Annexin V+, PMPs+, and CD45+ increased | (Ayers et al. 2009) | |
Patients |
CD31+/CD42- CD31+/Annexin V+ CD62E+ |
↑ ↑ ↑ |
Plasma | CPAP decreased CD62E+ | (Yun et al. 2010) | |
Patients (desaturators vs nondesaturators) |
CD146+ | ─ | Plasma | • CD66B+ and CD62L+ increased in OSA (desaturators) • OSA (desaturators)-MVs induce endothelial dysfunction |
(Priou et al. 2010) | |
Patients (2 week CPAP withdrawal) |
CD62E+
CD31+/CD41- |
↑ ─ |
Plasma | No changes in CD66B+, CD45+, and PMPs after a 2 week CPAP withdrawal | (Ayers et al. 2013) | |
Patients | CD146+ | ─ | Plasma | OSA-MVs carry VEGF and stimulate angiogenesis | (Tual-Chalot et al. 2014) | |
Patients | EC-EVs not assessed | Plasma | CD41+ and annexin V+ increase in the evening and with severity | (Bikov et al. 2017) | ||
Healthy volunteers exposed to human intermittent hypoxia (IH) | Endothelial exosomes | ↑ | Plasma | IH-induced exosomes cause endothelial dysfunction | (Khalyfa et al. 2016) |
Description of symbols: + indicates EVs positive, - indicates EVs negative, ↑ indicates increased EV levels, ─ indicates no change in EV levels.
Abbreviations: MVs; microvesicles, PMVs; platelet microvesicles, PH; Pulmonary hypertension, IPAH; Idiopathic pulmonary arterial hypertension, CTEPH; chronic thromboembolic pulmonary hypertension, ARDS; Acute respiratory distress syndrome, ALI; Acute Lung injury, VILI; ventilator-induced lung injury, BAL; Bronchoalveolar lavage, COPD; chronic obstructive pulmonary disease, OSA; obstructive sleep apnea, CPAP; continuous positive airway pressure.